Azaribine in the treatment of psoriasis. A low dose, double-blind evaluation.
D000328:Adult; D000368:Aged; D001380:Azauridine / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001706:Biopsy; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D002986:Clinical Trials as Topic; D005260:Female; D006400:Hematocrit; D006801:Humans; D008297:Male; D008875:Middle Aged; D009963:Orotic Acid / Q000652:urine; D010919:Placebos; D011565:Psoriasis / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism / Q000652:urine; D011743:Pyrimidines / Q000378:metabolism
D010919:Placebos; D011743:Pyrimidines; D009963:Orotic Acid; D001380:Azauridine; D002262:Carboxy-Lyases